Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 50mg | $29.00 | $0.58/mg | Out of stock | Jul 7 |
| vial | 100mg | $49.00 | $0.49/mg | In stock | Jul 7 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHK-Cu is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Reta One Labs sell GHK-Cu?
Yes — Reta One Labs currently lists GHK-Cu in 2 variants starting at $49.00 ($0.49/mg).
Is Reta One Labs's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 2 Certificates of Analysis for Reta One Labs's GHK-Cu, with the most recent showing 99.7% purity. Reta One Labs holds an overall trust grade of B (89/100) across all 41 COAs on file.
What is Reta One Labs's trust grade for GHK-Cu?
Reta One Labs has an overall Disclosed Labs trust grade of B (89/100), computed from 41 COAs across all peptides. The most recent GHK-Cu COA was issued by Chromate.
Where is the cheapest GHK-Cu?
As of the latest data, Sunrise Bioresearch offers GHK-Cu at $0.09/mg — compare with Reta One Labs's listing at $0.49/mg. See the full GHK-Cu price comparison.
Is GHK-Cu legal to buy?
GHK-Cu is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| GK1000426 | — | 99.9% | Kovera Labs | Endotoxin, Sterility, Heavy metals | Confirmed1 flag | View |
Disclosed Labs